| P50 | author | Federico G. Hoffmann | Q21391416 |
| | Philippe Lemey | Q28322657 |
| P2093 | author name string | Charles Wood | |
| | Hong Zhang | |
| | Ruth M Ruprecht | |
| | For Yue Tso | |
| | Robert A Rasmussen | |
| | Damien C Tully | |
| P2860 | cites work | CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice | Q24286950 |
| | Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251... | Q24798276 |
| | Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant | Q24815687 |
| | Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial | Q28305565 |
| | Not so different after all: a comparison of methods for detecting amino acid sites under selection | Q28306719 |
| | Antibody neutralization and escape by HIV-1 | Q29547345 |
| | Unifying the epidemiological and evolutionary dynamics of pathogens | Q29619092 |
| | SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys | Q30372757 |
| | Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. | Q30420728 |
| | Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. | Q33372270 |
| | Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels | Q33780649 |
| | Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity | Q33785035 |
| | Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection | Q33825654 |
| | The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner | Q33883936 |
| | Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV) | Q34060230 |
| | Diversity considerations in HIV-1 vaccine selection | Q34136023 |
| | Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques | Q34301728 |
| | SIV/HIV-1 chimeric viruses having HIV-1 env gene: a new animal model and a candidate for attenuated live vaccine | Q73480875 |
| | Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems | Q74220155 |
| | AIDS vaccine development and challenge viruses: getting real | Q79330996 |
| | Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage | Q34338411 |
| | The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. | Q34341843 |
| | The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. | Q34342352 |
| | Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity | Q35101464 |
| | Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease | Q35127401 |
| | Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies | Q35857254 |
| | Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. | Q35857408 |
| | Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. | Q35857683 |
| | An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys | Q35860563 |
| | Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys | Q35885915 |
| | Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease | Q35887052 |
| | Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses | Q36424574 |
| | The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection | Q36483346 |
| | Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline | Q36526893 |
| | Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. | Q36649240 |
| | Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 | Q36690500 |
| | HIV-1 vaccine development: progress and prospects | Q36718578 |
| | Immune responses to HIV Gp120 that facilitate viral escape | Q36723993 |
| | In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity | Q36825840 |
| | Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes | Q36960293 |
| | N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies | Q37010852 |
| | Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins | Q37742938 |
| | Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques | Q39193008 |
| | Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand | Q39358681 |
| | Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges | Q39385001 |
| | Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing | Q39457075 |
| | Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression | Q39534825 |
| | Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course | Q39605628 |
| | Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. | Q39685744 |
| | Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. | Q39869632 |
| | Effects of mutations in constant regions 3 and 4 of envelope of simian immunodeficiency virus | Q41326245 |
| | Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. | Q41986204 |
| | Posttranslational modifications within the HIV-1 envelope glycoprotein which restrict virus assembly and CD4-dependent infection | Q44030866 |
| | Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection | Q45419055 |
| | Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. | Q45938142 |
| | Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression | Q47872743 |
| | Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission | Q47878972 |
| | Convergent evolution of SIV env after independent inoculation of rhesus macaques with infectious proviral DNA | Q57697579 |
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Zambia | Q953 |
| | Macaca | Q177601 |
| P304 | page(s) | 1817-1828 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | AIDS | Q4651863 |
| P1476 | title | A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression | |
| P478 | volume | 23 | |